← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

BRAF V600 Mutant Melanoma

MONDO:0005012 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 40 citations openscientist · 60 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

BRAF V600 mutant melanoma is a cutaneous melanoma subtype defined by an activating somatic missense mutation at BRAF codon 600 (most commonly V600E) that produces a RAS-independent, constitutively active BRAF kinase driving the RAS-RAF-MEK-ERK (MAPK) cascade; BRAF mutations occur in roughly 40-50% of cutaneous melanomas.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 95% BRAFV600 (class I) is a RAS-independent activating mutant that constitutively activates the RAS/RAF/MEK/ERK cascade
Falcon states the RAS-independent constitutive activation of the MAPK cascade directly, and elsewhere gives the ~50% melanoma mutation frequency.
DOI:10.3390/ph18081235
openscientist CONCORDANT 95% produces a constitutively active kinase domain that drives oncogenesis independent of upstream RAS activation
OpenScientist matches the constitutive, RAS-independent kinase mechanism and cites the 40-50% mutation frequency in cutaneous melanoma.
PMID:39961465, PMID:33801689

Among BRAF V600 mutations, V600E is dominant (~79%), followed by V600K, V600R, and V600M, with non-V600 substitutions rarer; the V600E/V600K variants account for the vast majority of clinically actionable melanoma cases.

UNANIMOUS INTEGRATED
genetic_factor
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% Among BRAF V600 mutations, the distribution is: V600E (79%), V600K (12%), V600R (5%), and V600M (4%)
OpenScientist gives the precise V600 subtype distribution.
PMID:22536370
falcon CONCORDANT 85% somatic BRAF variants occur in ~50% of melanomas; most are codon-600 substitutions. V600E accounts for ~70–88% of BRAF-positive melanomas; V600K ~10–20%; non-V600 ~11%
Falcon reports the same V600E-dominant spectrum but as ranges (V600E ~70-88%, V600K ~10-20%) rather than the single-point percentages OpenScientist gives — overlapping and compatible.

BRAF-mutant melanoma is preferentially associated with younger age, intermittent (recreational) rather than chronic sun exposure, and trunk localization, and arises on a background of UV-driven melanocyte mutagenesis.

UNANIMOUS INTEGRATED
epidemiologypathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% BRAF-mutant melanomas are reported to be more frequent in younger patients and those with intermittent (occasional) sun exposure compared with chronically sun-exposed individuals
Falcon reports the younger-age and intermittent-sun-exposure enrichment qualitatively.
DOI:10.3390/cancers15164026
openscientist CONCORDANT 90% Associations with BRAF mutation were as follows: male gender [odds ratio (OR) = 2.4], younger age (OR = 2.7), superficial spreading (OR = 15.6) and nodular melanoma (OR = 9.5), trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)
OpenScientist quantifies the same associations with odds ratios from the Colombino cohort, adding male sex and histologic-subtype enrichment.
PMID:25357015

The V600E substitution acts as a phosphomimetic that increases BRAF kinase activity several-hundred-fold over wild-type, and the mutant signals as a monomer, explaining its RAS-independence.

UNANIMOUS INTEGRATED
gene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 90% V600E is described as a phosphomimetic with ~480-fold increased kinase activity and associated with increased cell growth
Falcon gives the phosphomimetic mechanism and ~480-fold activation.
DOI:10.3390/ph18081235
openscientist CONCORDANT 85% Wild-type BRAF kinase activity is ~70-fold lower than V600E mutant BRAF.
OpenScientist gives the same order-of-magnitude constitutive activation (~500-fold in its variant table) and adds that the mutant signals as a monomer.

FDA-approved BRAF plus MEK inhibitor combinations (dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+binimetinib) are the standard targeted therapy for BRAF V600 melanoma and achieve high objective response rates (~60-70%).

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Approved combinations are widely used in advanced disease; guideline notes include vemurafenib+cobimetinib, dabrafenib+trametinib, and encorafenib+binimetinib
Falcon enumerates the three approved BRAF/MEK inhibitor combinations from the SEOM-GEM guideline.
DOI:10.1007/s12094-024-03497-2
openscientist CONCORDANT 90% FDA-approved BRAF and MEK inhibitor combinations that achieve objective response rates of ~60–70%
OpenScientist gives the same drug combinations and the ~60-70% ORR, with a detailed approval-year and per-trial efficacy table.

Acquired resistance to BRAF/MEK inhibition develops in most patients and is multifactorial: MAPK reactivation (secondary NRAS or MEK mutations, BRAF amplification or splice variants), PI3K/AKT bypass signaling, and phenotype switching.

UNANIMOUS INTEGRATED
pathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% therapy response followed by adaptive/acquired resistance (MAPK reactivation, phenotype switching, RTK/PI3K bypass, autophagy)
Falcon lists MAPK reactivation, RTK/PI3K bypass, and phenotype switching as the resistance routes (and elsewhere quantifies MAPK reactivation in ~80% of resistant tumors).
DOI:10.3390/cancers15164026
openscientist CONCORDANT 90% Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions and the appearance of secondary NRAS(Q61) mutations or MEK1(Q56P) or MEK1(E203K) mutations
OpenScientist specifies the same MAPK-reactivation mechanism with the exact secondary NRAS/MEK mutations driving resistance.
PMID:23569304

BRAF V600E drives metabolic reprogramming toward aerobic glycolysis (Warburg effect) by suppressing MITF and PGC1-alpha, and BRAF inhibition reverses this by elevating oxidative phosphorylation — a metabolic plasticity implicated in drug resistance.

SINGLE LEAD
pathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation
OpenScientist develops the glycolysis/OXPHOS metabolic-reprogramming axis and the MITF-PGC1-alpha suppression mechanism as a distinct resistance dimension.
PMID:38972133, PMID:24610826
falcon SILENT —
Falcon notes MITF-high/MITF-low phenotype switching but does not cover the glycolysis-to-OXPHOS metabolic reprogramming or the MITF-PGC1-alpha metabolic axis.

Brain metastasis is a frequent and prognostically important feature of BRAF V600 melanoma and a major driver of therapy selection.

UNANIMOUS INTEGRATED
phenotypeprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 70% brain metastases occur in ~40–50% of patients with cutaneous melanoma and are highlighted as a major clinical problem
Falcon reports a high cumulative brain-metastasis burden (~40-50% of cutaneous melanoma patients) as a major clinical problem.
DOI:10.1056/evidoa2400087
openscientist CONCORDANT 70% ~32% of advanced cases have brain metastases at presentation
OpenScientist reports ~32% brain metastases at presentation — a lower figure framed as baseline-at-presentation rather than Falcon's cumulative ~40-50%; a quantitative/framing difference, not a contradiction.
PMID:34243078

In metastatic BRAF V600 melanoma, treatment sequencing matters: immunotherapy-first (or a short targeted-induction "sandwich") sequencing improves long-term survival and reduces brain metastases relative to targeted-therapy-first.

MAJORITY LEAD
treatmentprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 90% confirm immunotherapy as the preferred first-line treatment approach for most patients with BRAFV600-mutant metastatic melanoma
Falcon presents the SECOMBIT 4-year survival and brain-metastasis-free-survival data and the authors' immunotherapy-first conclusion in detail.
DOI:10.1038/s41467-023-44475-6, DOI:10.1056/evidoa2400087
openscientist PARTIAL 45% In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy
OpenScientist frames targeted therapy and immunotherapy as first-line alternatives per European guidelines but does not report the SECOMBIT sequencing outcomes or an immunotherapy-first-superiority conclusion.
PMID:35623961

Narrative

Overview

Both providers frame BRAF V600 mutant melanoma as a MAPK-driven cutaneous melanoma subtype centered on constitutive, RAS-independent BRAF kinase activation, melanocyte proliferation, and high responsiveness to combined BRAF plus MEK inhibition, with acquired resistance and brain metastasis as the dominant clinical challenges.

Agreement

The two reports agree on the core driver biology (activating codon-600 BRAF mutation, V600E dominant, constitutive MAPK/ERK signaling), the several-hundred-fold kinase hyperactivation, the etiologic enrichment for younger patients and intermittent UV exposure, the three approved BRAF/MEK inhibitor combinations with ~60-70% response rates, the multifactorial acquired resistance driven by MAPK reactivation and PI3K/AKT bypass, and the clinical prominence of brain metastasis.

Divergence

Falcon emphasized recent clinical-sequencing evidence — SECOMBIT 4-year survival and brain-metastasis-free-survival, NeoTrio neoadjuvant, and adjuvant D/T-vs-anti-PD-1 data — and concluded immunotherapy-first is preferred for most patients. OpenScientist was broader and more mechanistic, uniquely developing the glycolysis/OXPHOS metabolic-reprogramming axis (MITF-PGC1-alpha suppression), precise V600 subtype percentages, ctDNA prognostics, and a detailed diagnostics/ testing-methods survey. Quantitative differences (V600E ~70-88% vs 79%; brain metastases ~40-50% cumulative vs ~32% at presentation) are framing/coverage differences, not contradictions.

Integration

Promoted into kb/disorders/BRAF_V600_Mutant_Melanoma.yaml: the BRAF V600 driver and subtype entries (V600E/V600K/V600R/V600M), the constitutive-MAPK pathophysiology and phosphomimetic gene-function detail, the intermittent-UV/younger-age etiology, the approved BRAF/MEK inhibitor combinations, the acquired-resistance node (MAPK reactivation plus PI3K/AKT bypass), and brain metastasis as a prognostic phenotype.

Not integrated (leads)

Retained as research leads pending focused curator review: the glycolysis/OXPHOS metabolic-reprogramming resistance axis (OpenScientist-only), and the detailed metastatic sequencing/SECOMBIT and neoadjuvant/adjuvant regimen comparisons, which need dedicated evidence curation before promotion to first-class disease assertions.

Cross-provider synthesis comparing the falcon (clinical-trial and sequencing focused) and openscientist (comprehensive, 15-section, mechanistic) BRAF V600 melanoma reports. No direct contradictions were found; divergence is coverage/emphasis (metabolic reprogramming, subtype precision, and treatment-sequencing depth) plus minor quantitative framing differences. best_matching_text values are verbatim excerpts from the two report files; literature evidence snippets are intentionally left to the main disorder-YAML curation pipeline.